Covance Softsol Ltd vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of Covance Softsol Ltd (COVANCE) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
Covance Softsol Ltd vs TORRENT PHARMACEUTICALS L are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.
- Valuation31
- Profitability31
- Growth02
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
COVANCE takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
COVANCE takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
TORNTPHARM takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free."]
- − ["The company has delivered a poor sales growth of -66.3% over past five years.", "The company has delivered a poor profit growth of -56.8% over past five years."]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 67.6%"]
- − ["Stock is trading at 20.67 times its book value", "Company has a high debt to equity ratio of 1.79."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.